Brincidofovir

An antiviral medication used to treat certain viral infections

Brincidofovir
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Brincidofovir is an antiviral drug that is used to treat certain viral infections. It is a lipid conjugate of cidofovir, designed to improve the delivery and efficacy of the drug while reducing its toxicity.

Mechanism of Action

Brincidofovir works by inhibiting viral DNA polymerase, an enzyme critical for viral DNA replication. By blocking this enzyme, brincidofovir prevents the virus from multiplying and spreading within the host organism.

Clinical Uses

Brincidofovir is primarily used in the treatment of infections caused by double-stranded DNA viruses, including:

• Cytomegalovirus (CMV)
• Adenovirus
• Smallpox

It is particularly useful in immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation.

Pharmacokinetics

Brincidofovir is administered orally and is absorbed into the bloodstream, where it is converted into its active form. The lipid conjugation allows for better cellular uptake and distribution, enhancing its antiviral activity while minimizing renal toxicity, a common side effect associated with cidofovir.

Side Effects

Common side effects of brincidofovir include:

• Diarrhea
• Nausea
• Vomiting

Less common but serious side effects can include liver enzyme abnormalities and gastrointestinal disturbances.

Development and Approval

Brincidofovir was developed by Chimerix, a biopharmaceutical company. It has undergone various clinical trials to assess its efficacy and safety in treating viral infections. The drug has been granted orphan drug status for certain indications, reflecting its importance in treating rare conditions.

Related pages

• Antiviral drug
• Cidofovir
• DNA polymerase
• Immunocompromised

• 
  Brincidofovir